# Cairo University: Phase 3 study in Vitiligo, Non-Segmental Vitiligo (NSV) (35 participants)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | Cairo University |
| Sponsor type | Academic and hospital |
| Study | Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study. |
| NCT ID | NCT07904910 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Vitiligo; Non-Segmental Vitiligo (NSV); Stable Vitiligo |
| Intervention types | drug, device |
| Target enrollment | 35 |
| Site countries | Egypt |
| Posted | 2026-10-29 |
| Planned start | 2026-05-15 |
| Event | Newly registered study |
| Event date | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- Phase 3: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07904910). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.